Evaluation of the Pharmacokinetic Interactions and Safety of Atogepant Coadministered with Esomeprazole

References

• Buse DC , ManackAN , FanningKMet al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache52(10), 1456–1470 (2012).
   PubMed Web of Science ®Google Scholar
• Burch RC , BuseDC , LiptonRB. Migraine: Epidemiology, Burden, and Comorbidity. Neurol. Clin.37(4), 631–649 (2019).
   PubMed Web of Science ®Google Scholar
• Bigal ME , LiptonRB. The epidemiology, burden, and comorbidities of migraine. Neurol. Clin.27(2), 321–334 (2009).
   PubMed Web of Science ®Google Scholar
• Katic BJ , GoldenW , CadyRK , HuXH. GERD prevalence in migraine patients and the implication for acute migraine treatment. J. Headache Pain10(1), 35–43 (2009).
   PubMed Web of Science ®Google Scholar
• Lankarani KB , AkbariM , TabriziR. Association of Gastrointestinal Functional Disorders and Migraine Headache: a Population Base Study. Middle East J. Dig. Dis.9(3), 139–145 (2017).
   PubMedGoogle Scholar
• Korolainen MA , TuominenS , KurkiSet al. Burden of migraine in Finland: multimorbidity and phenotypic disease networks in occupational healthcare. J. Headache Pain21(1), 8 (2020).
   PubMed Web of Science ®Google Scholar
• Hormati A , AkbariN , SharifipourEet al. Migraine and gastric disorders: are they associated? J. Res. Med. Sci. 24, 60 (2019).
   PubMed Web of Science ®Google Scholar
• Peres MFP , MercanteJPP , ToboPR , KameiH , BigalME. Anxiety and depression symptoms and migraine: a symptom-based approach research. J. Headache Pain18(1), 37 (2017).
   PubMed Web of Science ®Google Scholar
• Ly HG , WeltensN , TackJ , Van OudenhoveL. Acute Anxiety and Anxiety Disorders Are Associated With Impaired Gastric Accommodation in Patients With Functional Dyspepsia. Clin. Gastroenterol Hepatol.13(9), 1584–1591; e3 (2015).
   PubMed Web of Science ®Google Scholar
• Haug TT , MykletunA , DahlAA. Are anxiety and depression related to gastrointestinal symptoms in the general population?Scand. J. Gastroenterol.37(3), 294–298 (2002).
   PubMed Web of Science ®Google Scholar
• Minen MT , BegasseDe Dhaem O , KroonVan Diest Aet al. Migraine and its psychiatric comorbidities. J. Neurol. Neurosurg. Psychiatry87(7), 741–749 (2016).
   PubMed Web of Science ®Google Scholar
• Deeks ED . Atogepant: First Approval. Drugs82(1), 65–70 (2022).
   PubMed Web of Science ®Google Scholar
• Boinpally R , JakateA , ButlerM , BorbridgeL , PericlouA. Single-Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open-Label, Phase I Trial. Clin. Pharmacol. Drug Dev.10(7), 726–733 (2021).
   PubMed Web of Science ®Google Scholar
• AbbVie Inc. QULIPTA (Atogepant) [ package insert]. IL, USA (2023).
   Google Scholar
• Boinpally R , SpaventaJ , ChenK , ButlerM. Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial. Clin. Drug Investig.41(6), 557–567 (2021).
   PubMed Web of Science ®Google Scholar
• Ankrom W , XuJ , ValleeMHet al. Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants. J. Clin. Pharmacol.60(9), 1157–1165 (2020).
   PubMed Web of Science ®Google Scholar
• Boinpally R , ForsytheC , BorbridgeLet al. Evaluation of pharmacokinetic interactions and safety of atogepant coadministered with quinidine gluconate. [ abstract]. Neurology96(Suppl. 15), 1512 (2021).
   Web of Science ®Google Scholar
• Al-Hassany L , MaassenvandenbrinkA. Drug interactions and risks associated with the use of triptans, ditans and monoclonal antibodies in migraine. Curr. Opin. Neurol.34(3), 330–338 (2021).
   PubMed Web of Science ®Google Scholar
• Szkutnik-Fiedler D . Pharmacokinetics, Pharmacodynamics and drug–drug interactions of New Anti-Migraine Drugs-Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies. Pharmaceutics12(12), 1180 (2020).
   PubMed Web of Science ®Google Scholar
• Joshi S , TepperSJ , LucasS , RasmussenS , NelsonR. A narrative review of the importance of pharmacokinetics and drug–drug interactions of preventive therapies in migraine management. Headache61(6), 838–853 (2021).
   PubMed Web of Science ®Google Scholar
• Kaytser V , ZhangP. Non-interacting, Non-opioid, and Non-barbiturate Containing Acute Medication Combinations in Headache: A Pilot Combinatorics Approach Based on DrugBank Database. Front. Neurol.12, doi:10.3389/fneur.2021.632830 (2021).
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM , BoinpallyR , DeAbreu Ferreira Ret al. Phase Ib, open-label, fixed-sequence, drug–drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine. Headache63(3), 322–332 (2023).
   PubMed Web of Science ®Google Scholar
• Boinpally R , JakateA , ButlerM , PericlouA. Atogepant and sumatriptan: no clinically relevant drug–drug interactions in a randomized, open-label, crossover trial. Pain Manag.12(4), 499–508 (2022).
   PubMed Web of Science ®Google Scholar
• Zhong XF , ZhouG , XuSMet al. Pharmacokinetics of esomeprazole magnesium after single oral doses in healthy subjects: bioequivalence study and food effects. Clin Pharmacol. Drug Dev.11(11), 1308–1313 (2022).
   PubMed Web of Science ®Google Scholar
• Rosenfeld MG , MermodJJ , AmaraSGet al. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature304(5922), 129–135 (1983).
   PubMed Web of Science ®Google Scholar
• Jansen I , UddmanR , HochermanMet al. Localization and effects of neuropeptide Y, vasoactive intestinal polypeptide, substance P, and calcitonin gene-related peptide in human temporal arteries. Ann. Neurol.20(4), 496–501 (1986).
   PubMed Web of Science ®Google Scholar
• Mulderry PK , GhatkiMA , SpokksRAet al. Differential expression of α-CGRP and β-CGRP by primary sensory neurons and enteric autonomic neurons of the rat. Neuroscience25(1), 195–205 (1988).
   PubMed Web of Science ®Google Scholar
• Falkenberg K , BjergHR , OlesenJ. Two-h CGRP Infusion Causes Gastrointestinal Hyperactivity: Possible Relevance for CGRP Antibody Treatment. Headache60(5), 929–937 (2020).
   PubMed Web of Science ®Google Scholar
• Boinpally R , LuK. Evaluation of the Pharmacokinetic Interaction and Safety of Ubrogepant Coadministered With Esomeprazole Magnesium. Clin. Pharmacol. Drug Dev.11(2), 270–277 (2022).
   PubMed Web of Science ®Google Scholar
• Hutchinson S , LiptonRB , AilaniJet al. Characterization of Acute Prescription Migraine Medication Use: Results From the CaMEO Study. Mayo Clin. Proc.95(4), 709–718 (2020).
   PubMed Web of Science ®Google Scholar
• Nexium (esomeprazole magnesium) [ package insert:]. AstraZeneca Pharmaceuticals LP, DE, USA (2014).
   Google Scholar
• Goadsby PJ , DodickDW , AilaniJet al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. Lancet Neurol.19(9), 727–737 (2020).
   PubMed Web of Science ®Google Scholar
• Singh A , BalasundaramMK. Atogepant for migraine prevention: A systematic review of efficacy and safety. Clin. Drug Investig.42(4), 301–308 (2022).
   PubMed Web of Science ®Google Scholar
• Alhankawi D , SharmaS , SunK , TheiseN , ParkJ. Proton pump inhibitor-induced liver injury: 2422. The Am. J. Gastroenterol.113, S1349–S1350 (2018).
   Web of Science ®Google Scholar
• Ailani J , LiptonRB , GoadsbyPJet al. Atogepant for the preventive treatment of migraine. N. Engl. J. Med.385(8), 695–706 (2021).
   PubMed Web of Science ®Google Scholar